GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have received a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $8.18.

GDRX has been the subject of several research analyst reports. Wells Fargo & Company lowered their price target on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a report on Friday, February 28th. Morgan Stanley lowered their target price on GoodRx from $7.00 to $6.00 and set an “equal weight” rating for the company in a report on Tuesday, December 17th. Citigroup cut their price target on GoodRx from $7.00 to $6.25 and set a “buy” rating on the stock in a research note on Friday, January 10th. Barclays lowered their price objective on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Finally, Mizuho began coverage on shares of GoodRx in a research report on Wednesday, December 4th. They set a “neutral” rating and a $5.00 target price on the stock.

GoodRx Price Performance

Shares of NASDAQ:GDRX opened at $4.64 on Friday. GoodRx has a one year low of $4.09 and a one year high of $9.26. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company has a market cap of $1.77 billion, a price-to-earnings ratio of -154.67, a PEG ratio of 2.46 and a beta of 1.25. The firm has a 50 day simple moving average of $4.73 and a 200 day simple moving average of $5.68.

Institutional Investors Weigh In On GoodRx

A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its holdings in GoodRx by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company’s stock valued at $38,935,000 after buying an additional 460,753 shares during the period. Rubric Capital Management LP lifted its stake in shares of GoodRx by 25.2% in the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after purchasing an additional 943,226 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of GoodRx by 22.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company’s stock valued at $9,264,000 after purchasing an additional 369,553 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of GoodRx during the 3rd quarter valued at about $11,295,000. Finally, Clearbridge Investments LLC acquired a new stake in GoodRx during the fourth quarter worth approximately $5,863,000. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.